At first, Chinese pharmaceutical companies rushed to make similar versions of blockbuster weight-loss drugs, such as Wegovy and Ozempic ... such as sleep apnoea, fatty liver disease, chronic kidney ...

The treatment also reduced liver fat — an exciting finding in China, where fatty liver disease is prevalent ... revenue of 704 million Danish kroner ($110 million) in China to Wegovy’s local launch.

Gyre Therapeutics has a unique business model for evaluating and commercializing drugs in China. Find out why GYRE stock is a ...